Lenacapavir: A Twice-Yearly Injectable for HIV Preexposure Prophylaxis
Lenacapavir provides a long-acting injectable option for people seeking a pharmacologic prevention agent against HIV-1. Despite injection-site reactions being relatively common, these did not present a barrier to treatment continuation among trial participants.
Authors
- Elizabeth M Sherman (ORCID: https://orcid.org/0000-0002-6559-0684)
- David E. Koren (ORCID: https://orcid.org/0000-0002-6601-9893)
- Elias B. Chahine (ORCID: https://orcid.org/0000-0003-1775-9497)
Institutions
- Nova Southeastern University (US)
- Memorial Healthcare System (US)
- Temple University Health System (US)
- Palm Beach Atlantic University (US)
Publication Details
- Journal
- Annals of Pharmacotherapy
- Published
- 2025-10-23
- DOI
- https://doi.org/10.1177/10600280251379877
- Citations
- 1
- Primary Topic
- HIV/AIDS Research and Interventions
- Type
- article
- Field-Weighted Citation Impact
- 1.40